Haustein Silke V, Mack Eberhard, Starling James R, Chen Herbert
Section of Endocrine Surgery, Department of Surgery, University of Wisconsin Medical School, Madison, WI 53792, USA.
Surgery. 2005 Dec;138(6):1066-71; discussion 1071. doi: 10.1016/j.surg.2005.05.024.
Intraoperative parathyroid hormone (PTH) testing has been shown to accurately define adequacy of parathyroid resection in patients with primary hyperparathyroidism (HPT) and alters the operative management in 10% to 15% of cases. However, the benefit of this technique in patients with tertiary HPT after renal transplantation undergoing parathyroidectomy is unclear.
Intraoperative PTH was measured in 32 consecutive patients undergoing parathyroidectomy for tertiary HPT after renal transplantation between March 2001 and November 2004 by using the Elecsys assay at baseline and, subsequently, 5, 10, and 15 minutes after curative resection. The outcomes of these patients were evaluated.
All patients were cured after surgery. Of the 32 patients, 29 were found to have parathyroid hyperplasia, while 1 had a single adenoma and 2 had double adenomas. The average drop in intraoperative PTH levels after curative resection was 69 +/- 3.5% at 5 min., 77 +/- 2.3% at 10 minutes, and 83 +/- 3.4% at 15 minutes. PTH testing changed the intraoperative management in 5 (16%) patients. One patient with a single adenoma and 2 patients with double adenomas had a >50% drop at 10 minutes. after excision; therefore, the operation was terminated without further resection. Two patients did not have a >50% drop at 10 minutes after 3.5 gland resection. These patients were explored further, and additional supernumerary parathyroid glands were identified and resected. After resection of these additional glands, the PTH fell by >50%, indicating cure.
In patients undergoing parathyroidectomy for tertiary HPT after renal transplantation, a decrease in intraoperative PTH levels >50% at 10 minutes after completion of the operation indicated adequate resection. Furthermore, intraoperative PTH testing altered the operative management in 16% of patients. Therefore, similar to its role in patients with primary HPT, intraoperative PTH testing appears to play an equally important role in the management of patients with tertiary HPT undergoing parathyroidectomy.
术中甲状旁腺激素(PTH)检测已被证明能准确界定原发性甲状旁腺功能亢进症(HPT)患者甲状旁腺切除是否充分,并在10%至15%的病例中改变手术管理方式。然而,该技术在肾移植后发生三发性HPT并接受甲状旁腺切除术的患者中的益处尚不清楚。
2001年3月至2004年11月期间,连续32例因肾移植后三发性HPT接受甲状旁腺切除术的患者,术中使用电化学发光免疫分析法在基线时以及根治性切除后5、10和15分钟测量PTH。对这些患者的结局进行评估。
所有患者术后均治愈。32例患者中,29例为甲状旁腺增生,1例为单发腺瘤,2例为双发腺瘤。根治性切除后,术中PTH水平在5分钟时平均下降69±3.5%,10分钟时下降77±2.3%,15分钟时下降83±3.4%。PTH检测改变了5例(16%)患者的术中管理方式。1例单发腺瘤患者和2例双发腺瘤患者在切除后10分钟时下降>50%;因此,手术终止,未进一步切除。2例患者在切除3.5个腺体后10分钟时下降未>50%。对这些患者进行了进一步探查,发现并切除了额外的甲状旁腺。切除这些额外腺体后,PTH下降>50%,表明已治愈。
对于肾移植后三发性HPT接受甲状旁腺切除术的患者,手术完成后10分钟时术中PTH水平下降>50%表明切除充分。此外,术中PTH检测改变了16%患者的手术管理方式。因此,与在原发性HPT患者中的作用类似,术中PTH检测在接受甲状旁腺切除术的三发性HPT患者管理中似乎起着同样重要的作用。